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Abstract
Background: To identify spatiotemporal gait parameters and plantar pressure distribution during barefoot walking
in people with gout and people with asymptomatic hyperuricemia by comparing them to healthy individuals with
normal serum urate concentrations.
Methods: Eighty-seven participants were included: 24 with gout, 29 with asymptomatic hyperuricemia and 34 age-
and sex-matched normouricemic control participants. Spatiotemporal parameters of gait were assessed during level
barefoot walking using a GAITRite® walkway. Peak plantar pressure and pressure time integrals were recorded using
a TekScan MatScan®. Results were adjusted for age and body mass index.
Results: Compared to normouricemic control participants, participants with gout demonstrated increased step time
(P = 0.022) and stance time (P = 0.022), and reduced velocity (P = 0.050). Participants with gout also walked with
decreased peak pressure at the heel (P = 0.012) and hallux (P = 0.036) and increased peak pressure (P < 0.001) and
pressure time integrals (P = 0.005) at the midfoot. Compared to normouricemic control participants, participants
with asymptomatic hyperuricemia demonstrated increased support base (P = 0.002), double support time (P < 0.001)
and cadence (P = 0.028) and reduced swing time (P = 0.019) and single support time (P = 0.020) as well as increased
pressure at the midfoot (P = 0.013), first metatarsal (P = 0.015) and second metatarsal (P = 0.007).
Conclusion: During barefoot walking, people with gout walk slower with plantar pressure patterns suggestive of
apropulsive and antalgic gait strategies. Individuals with asymptomatic hyperuricemia also demonstrate altered
barefoot gait patterns when compared to normouricemic control participants. Clinicians may consider dynamic gait
outcomes when assessing and managing foot and lower limb related pain and disability in individuals with gout
and asymptomatic hyperuricemia.
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Background
People with gout experience flares of severe inflamma-
tory arthritis as a response to the presence of urate crys-
tals deposited in joints and soft tissues [1, 2]. Gout most
commonly affects peripheral structures of the foot and
ankle with a propensity for the first metatarsophalangeal
joint and Achilles tendon [3, 4]. Although elevated
serum urate (hyperuricemia) is required for the develop-
ment of gout, not all individuals with hyperuricemia de-
velop symptomatic acute gouty arthritis [5]. However,
advanced imaging studies have identified urate depos-
ition and joint damage in foot and ankle structures in in-
dividuals with asymptomatic hyperuricemia [6–10].
People with gout report chronic and persistent foot and
lower limb impairments, even in the absence of acute arth-
ritis [11–16]. Furthermore, foot-related disability has been
associated with altered gait parameters in people with gout
[16] and may be mirrored in their plantar pressure patterns
which have been proposed to reflect pain-avoidance strat-
egies [13]. Individuals with asymptomatic hyperuricemia,
who lack any current or previous symptoms of acute gouty
arthritis or clinical evidence of urate deposition, also report
disabling foot pain and experience lower limb impairments
and activity limitations compared to healthy individuals
with normal urate levels [14]. However, it is unknown
whether their gait and plantar pressure patterns also differ
from healthy normouricemic individuals.
Previous plantar pressure research in gout has been
undertaken with patients wearing their own footwear
[13]. Many people with tophaceous gout of the foot re-
port difficulty in wearing and finding footwear that is ap-
propriate to their level of pain, disability and deformity
[17–22]. Footwear worn by people with gout has been
shown to be poorly fitting with minimal cushioning and
motion control properties [23]. Furthermore, over half
of people with gout wear shoes with flexion points prox-
imal to the level of the metatarsal heads which can limit
gait efficiency by inhibiting normal first metatarsopha-
langeal joint function during propulsion [24] and hence
may exacerbate the problems of efficient toe-off ob-
served in people with gout during shod walking [13].
Considering the important influence of footwear on foot
function, assessment of plantar pressure without the
confounding effect of footwear is warranted.
This study aimed to identify spatiotemporal gait pa-
rameters and plantar pressure distribution during level
barefoot walking in people with gout and people with




This investigation was a cross-sectional observational
study. Ethical approval for the study was obtained from
the Auckland University of Technology Ethical Commit-
tee (13/100) and Locality Assessment was obtained from
the Auckland District Health Board (ADHB) Research
Office (A + 5891). All participants provided written in-
formed consent prior to data collection.
Participants with gout were recruited from the ADHB
rheumatology clinic and met the 1977 preliminary
American Rheumatism Association (ARA) classification
criteria for gout [25]. Participants without gout were
recruited from the local community and were to have no
history of acute arthritis nor meet the ARA criteria. Par-
ticipants without gout underwent serum urate testing on
the day of the study using a Reflotron® Plus capillary test
and were stratified into either the asymptomatic hyper-
uricemia group (serum urate ≥0.41 mmol/L) or the nor-
mouricemic control group (serum urate <0.41 mmol/L,
6.8 mg/dL). The three diagnostic groups were age-and
sex-matched. Participants were excluded if they were
under 20 years of age; had a history of other inflamma-
tory arthritis; were experiencing an acute flare at the
time of the clinical visit; had foot and/or ankle surgery
in the previous 3 months; had lower limb amputation; or
were unable to walk 5 m unaided.
All data were collected during a single session at the
Auckland University of Technology Podiatry Clinic
(Auckland, New Zealand) by a single researcher (SS).
Demographic data were obtained from all participants
including age, gender, ethnicity, body mass index (BMI),
current medications and medical history. Peripheral sen-
sation was assessed using a 10 g Semmes-Weinstein
monofilament at the plantar hallux, first metatarsal head
and fifth metatarsal head. A loss of protective sensation
for each foot was defined if absent in at least two of the
three sites. Additionally, gout disease characteristics
were documented for participants with gout including
disease duration, flare history, presence of subcutaneous
tophi and tophus count.
Gait parameters
Spatial and temporal parameters of gait during level
barefoot walking were collected using the GAITRite sys-
tem (CIR Systems, Inc., New Jersey, US). The GAITRite
is a 700 cm × 90 cm electronic walkway with an active
sensor area of 610 cm long and 60 cm wide. The active
area contains 23,040 embedded pressure-activated sen-
sors with a spatial resolution of 1.27 cm and a sampling
rate of 120 Hz. All data was processed and stored by an
IBM compatible computer using GAITRite® gold, Ver-
sion 3.2b software. Participants were instructed to walk
at their own comfortable walking speed [26] from a
point 100 cm before the walkway and finishing 100 cm
past its end to ensure that when they reached the walk-
way they were walking at a normal speed and momen-
tum. Three trials of barefoot walking were recorded for
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each participant with adequate rest time between trials.
Prior to calculation of the gait parameters, the data was
reviewed on the monitor screen to ensure that right and
left footfalls had been correctly identified, and any
footfall not completely on the walkway at either end
was removed. For each trial the following temporal
and spatial parameters for right and left feet were
calculated: velocity (m/s), cadence (steps/min), step
length (cm), stride length (cm), support base (cm),
step time (s), swing time (s), stance time (s), and sin-
gle and double support time (s).
Plantar pressure
Dynamic plantar pressure measurements were captured
during level barefoot walking using the TekScan MatS-
can® system (Boston, MA, USA). The system consists of
a 5 mm thick platform (432 × 368 mm), comprising of
2288 resistive sensors (1.4 sensors/cm2) which sample
data at a frequency of 40 Hz. Data was collected using
the two-step gait initiation protocol [27] which required
the participant to step on the platform on their second
step. Prior to data acquisition participants were
instructed to familiarise themselves with the protocol
and line themselves up with the platform to ensure their
second step landed in the sensing area. Participants were
instructed to walk at their own natural comfortable
walking speed and to continue walking past the platform
for at least two more steps which ensured that a con-
stant velocity and momentum had been reached and
pressure data reflected their normal gait. Three trials
were recorded for each foot. The Research Foot® Version
6.61 was used to mask the foot into seven regions repre-
senting the heel, midfoot, first metatarsal, second meta-
tarsal, metatarsal three to five, the hallux, and the lesser
toes (Fig. 1). This masking method has demonstrated ex-
cellent reliability for the calculation of pressure parame-
ters (ICCs 0.96 to 0.99) [28]. Peak plantar pressure (kPa)
and pressure time integrals (kPa⋅s) were computed from
the software for each masked region.
Statistical analysis
All continuous outcomes were reviewed for normality
using the residuals from a linear model which included
relevant demographic covariates and the diagnostic
group as the independent variable. Mixed linear regres-
sion models were used which accounted for repeated
measures taken from right and left feet of each partici-
pant in which participant-specific and participant-nested
random effects for foot-side were added to the models.
This analysis produces results identical to an analysis of
measures averaged for each foot-side (if there are no
missing values) that allows for a between-foot-side cor-
relation as well as any reweighting required due to miss-
ing values. For the spatiotemporal gait parameters the
models also accounted for the time-based repeated-
measures using a scaled identity repeated covariance
structure which assumed the repeated-measures were in-
dependent and shared a common variance. For peak plan-
tar pressure and pressure time integrals, which were
measured at seven sites on the plantar foot (forming a
natural vector of related variables), in addition to the side-
and time-based repeated measures, a heterogeneous
Fig. 1 Masking of seven plantar regions
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compound symmetry covariance structure was employed
which allowed for separate variances for each site, as well
as different covariances (but equal correlations) between
each group of sites.
Adjustments for age group, ethnicity and BMI, which
were entered into each model simultaneously, were con-
sidered only if their level of observed significance
achieved at least 10 % on an F-test. These covariates
were not expected to behave as confounders due to the
frequency matching, but had the potential to decrease
residual variance as possible independent variables.
Potential covariates were also explored by reviewing box
plots of random effects by covariate group.
Two comparisons were considered: gout vs. normouri-
cemic control and asymptomatic hyperuricemic vs. nor-
mouricemic control, which were always tested separately.
All hypothesis tests (excluding covariate testing) were
carried out at a 5 % level of significance against two-sided
alternatives. No adjustment for multiplicity was used, but
all test-statistics (least-squares (L-S) means), their null
distributions and their observed significance levels were
reported. Data were analysed using IBM SPSS Statistics
version 20 and proc-mixed in SAS version 9.3.
Sample size
The study was powered to test hypotheses regarding
pre-planned analyses comparing normouricemic control
parameters with asymptomatic hyperuricemic and gout
parameters respectively. With respect to this analysis,
the target figures of 21 participants in the gout group,
29 in the asymptomatic hyperuricemia group and 34 in
the normouricemic control group are sufficient to detect
unadjusted effect sizes on continuous outcomes of 0.7
and 0.8 (moderate to large) between control and each
of the asymptomatic hyperuricemia and the gout
group, respectively. The achieved sample size im-
proved on these figures.
Results
Participant characteristics
A total of 87 participants were included: 24 with gout,
29 with asymptomatic hyperuricemia and 34 normouri-
cemic controls. Demographic and clinical characteristics
for the three groups are shown in Table 1. All partici-
pants were male with a mean (SD) age of 58 (15) years
and predominantly of European ethnicity (n = 68, 81 %).
The normouricemic control group had a significantly
lower mean BMI compared to the gout (P < 0.001) and
asymptomatic hyperuricemic (P < 0.001) groups. The nor-
mouricemic control group had a significantly lower preva-
lence of hypertension compared to the gout (P = 0.001)
and asymptomatic hyperuricemic (P = 0.023) groups and a
significantly lower prevalence of cardiovascular disease
compared to the gout group (P = 0.019). Disease charac-
teristics for the gout group are shown in Table 2. Partici-
pants with gout were found to have a mean (SD) disease
duration of 17 (11) years, with 71 % (n = 17) having
tophaceous gout and 96 % (n = 23) on urate lowering
therapy.
The distribution of residuals from the linear models
for all outcome measures demonstrated sufficient nor-
mality to carry out parametric testing. The effect of age
group and BMI as covariates were included in the final
models for all gait and plantar pressure parameters.
Table 3 displays the mean estimates and inferential sta-
tistics for the spatial and temporal gait parameters.
Table 1 Demographic and medical characteristics. Data are presented as mean (SD) unless otherwise specified
Variable Normouricemic control Gout Asymptomatic Hyperuricemia
N 34 24 29
Gender, male, n (%) 34 (100 %) 24 (100 %) 29 (100 %)
Age, years 58 (14) 58 (13) 58 (19)
Ethnicity, n (%) European 30 (88 %)
Māori 1 (3 %)
Pacific 0 (0 %)
Asian 3 (9 %)
European 14 (58 %)
Māori 1 (4 %)
Pacific 5 (21 %)
Asian 4 (17 %)
European 24 (83 %)
Māori 0 (0 %)
Pacific 3 (10 %)
Asian 2 (7 %)
BMI, kg/m2 25.0 (2.9) 30.2 (4.0)† 29.3 (5.9)†
Diuretic use, n (%) 4 (12 %) 3 (12 %) 7 (24 %)
Hypertension, n (%) 9 (26 %) 17 (70 %)† 16 (55 %)†
Cardiovascular disease, n (%) 1 (3 %) 7 (29 %)† 5 (17 %)
Diabetes, n (%) 2 (6 %) 4 (17 %) 1 (3 %)
Loss of protective sensation, n (%) Right 1 (3 %)
Left 1 (3 %)
Right 4 (17 %)
Left 6 (25 %)
Right 4 (14 %)
Left 4 (14 %)






†Significantly different from normouricemic control group (p < 0.05)
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Compared to normouricemic control participants, par-
ticipants with gout had significantly increased step time
(P = 0.022), increased stance time (P = 0.022) and de-
creased velocity (P = 0.050). Compared to normourice-
mic control participants, participants with asymptomatic
hyperuricemia had significantly increased support base
(P = 0.002), reduced swing time (P = 0.019), decreased
single support time (P = 0.020), increased double support
time (P < 0.001) and increased cadence (P = 0.028).
Table 4 displays the mean estimates and inferential
statistics for peak plantar pressure. Compared to nor-
mouricemic control participants, participants with gout
had significantly reduced pressure at the heel (P = 0.012)
and hallux (P = 0.036) and increased pressure at the
Table 2 Gout disease characteristics. Data are presented as
mean (SD) unless otherwise specified
Variable Gout
Disease duration, years 17 (11)
Age of onset, years 41 (18)
Number of flares in preceding 3 months 1.3 (1.4)
Presence of subcutaneous tophi, n (%) 17 (71 %)
Foot tophus count 1.9 (3.5)
Total tophus count 6.1 (8.7)
Colchicine use, n (%) 13 (54 %)
Urate lowering therapy, n (%) 23 (96 %)
Table 3 Spatial and temporal gait parameters. Results are presented adjusted for age and BMI
Parameter Least-squares
mean
Diff. 95 % CI p
Lower Upper
Step Length (cm) Normouricemic control 0.61
Gout 0.57 0.03 −0.02 0.08 0.168
Asymptomatic hyperuricemia 0.61 0.00 −0.05 0.05 0.985
Stride Length (cm) Normouricemic control 1.21
Gout 1.14 0.07 −0.04 0.17 0.200
Asymptomatic hyperuricemia 1.20 0.02 −0.08 0.11 0.763
Support Base (cm) Normouricemic control 0.08
Gout 0.10 −0.02 −0.03 0.00 0.102
Asymptomatic hyperuricemia 0.11 −0.03 −0.05 −0.01 0.002
Step Time (s) Normouricemic control 0.60
Gout 0.64 −0.04 −0.07 −0.01 0.022
Asymptomatic hyperuricemia 0.57 0.03 0.00 0.06 0.081
Swing Time (s) Normouricemic control 0.46
Gout 0.47 −0.02 −0.04 0.00 0.104
Asymptomatic hyperuricemia 0.43 0.03 0.01 0.05 0.019
Stance Time (s) Normouricemic control 0.74
Gout 0.80 −0.06 −0.10 −0.01 0.022
Asymptomatic hyperuricemia 0.72 0.03 −0.02 0.07 0.266
Single Support Time (s) Normouricemic control 0.46
Gout 0.48 −0.02 −0.04 0.00 0.092
Asymptomatic hyperuricemia 0.43 0.03 0.00 0.05 0.020
Double Support Time (s) Normouricemic control 0.16
Gout 0.16 0.00 −0.04 0.04 0.857
Asymptomatic hyperuricemia 0.26 −0.10 −0.14 −0.06 <0.001
Velocity (m/s) Normouricemic control 1.03
Gout 0.91 0.11 0.00 0.23 0.050
Asymptomatic hyperuricemia 1.07 −0.05 −0.15 0.06 0.379
Cadence (steps/min) Normouricemic control 100.9
Gout 95.5 5.4 −0.7 11.5 0.080
Asymptomatic hyperuricemia 107.3 −6.5 −12.2 −0.7 0.028
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midfoot (P < 0.001). Compared to normouricemic control
participants, participants with asymptomatic hyperurice-
mia had significantly increased pressure at the midfoot (P
= 0.013), first metatarsal (P = 0.015) and second metatarsal
(P = 0.007). Examples of typical plantar pressure patterns
for normouricemic controls and people with asymptomatic
hyperuricemia and gout are presented in Fig. 2. Table 5 dis-
plays the mean estimates and inferential statistics for the
pressure time integrals. Compared to normouricemic con-
trol participants, participants with gout had significantly
increased pressure time integrals at the midfoot (P =
0.006), but no other differences were observed. No differ-
ences were observed for pressure time integrals between
the asymptomatic hyperuricemic participants and the nor-
mouricemic control participants (P > 0.05).
Discussion
Our study shows that people with gout and people with
asymptomatic hyperuricemia both demonstrate varia-
tions in gait parameters and plantar pressure distribution
during level barefoot walking when compared to nor-
mouricemic control participants.
During barefoot walking, people with gout walked
slower with increased time spent in step and stance phases
compared to the normouricemic control participants.
These findings are consistent with previous research
assessing people with gout during both shod and barefoot
walking [13, 16, 29]. Reduced gait speed is considered an
important characteristic of impaired physical performance
in daily activities in adults [30, 31] and has been associated
with self-reported foot-related functional limitation in
people with gout [16]. Functional gait limitations exhibited
by people with gout may result from several factors in-
cluding reduced lower limb muscle strength [15], loss of
normal joint function [14] and acquired gait strategies de-
veloped in an attempt to reduce or prevent pain [13, 16].
The increased midfoot and reduced hallux plantar pres-
sures observed in people with gout are also consistent
with previous research in which participants were assessed
during shod walking [13]. Previous studies have proposed
that reduced peak pressure beneath the hallux in people
with gout may reflect an attempt to offload pressure at the
first metatarsophalangeal joint due to pain [13]. This is
further emphasised in qualitative research in which people
with gout report attempting to walk more cautiously with
an adjusted foot position to relieve the big toe during
acute flares [32]. Additionally, inefficient first metatarso-
phalangeal joint function, previously observed in people
with gout [14], may further contribute to the apropulsive
gait strategies observed in the current study. In contrast
Table 4 Peak plantar pressure (kPa). Results are presented adjusted for age and BMI
Parameter Least-squares
mean
Diff. 95 % CI p
Lower Upper
Heel Normouricemic control 294.3
Gout 268.2 −26.1 −46.6 −5.6 0.012
Asymptomatic hyperuricemia 301.9 7.6 −12.4 27.5 0.456
Midfoot Normouricemic control 95.4
Gout 130.8 35.4 15.5 55.3 <0.001
Asymptomatic hyperuricemia 120.1 24.7 5.3 44.0 0.013
First Metatarsal Normouricemic control 211.5
Gout 229.6 18.2 −5.2 41.5 0.127
Asymptomatic hyperuricemia 239.7 28.3 5.6 50.9 0.015
Second Metatarsal Normouricemic control 292.6
Gout 287.1 −5.5 −26.9 15.8 0.611
Asymptomatic hyperuricemia 321.3 28.7 7.9 49.5 0.007
Third to Fifth Metatarsals Normouricemic control 252.3
Gout 244.1 −8.2 −29.6 13.2 0.454
Asymptomatic hyperuricemia 255.2 2.9 −17.9 23.7 0.785
Hallux Normouricemic control 233.3
Gout 208.4 −24.9 −48.1 −1.6 0.036
Asymptomatic hyperuricemia 241.9 8.6 −14.0 31.3 0.454
Lesser Toes Normouricemic control 105.9
Gout 121.8 15.9 −2.8 34.6 0.096
Asymptomatic hyperuricemia 107.2 1.4 −16.9 19.6 0.882
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Fig. 2 Examples of typical plantar pressure patterns from a control, asymptomatic hyperuricaemia and gout participant
Table 5 Pressure time integral (kPa⋅s). Results are presented adjusted for age and BMI
Parameter Least-squares
mean
Diff. 95 % CI p
Lower Upper
Heel Normouricemic control 61.50
Gout 54.68 −6.82 −13.75 0.12 0.054
Asymptomatic hyperuricemia 59.83 −1.67 −8.44 5.09 0.628
Midfoot Normouricemic control 23.48
Gout 32.66 9.18 2.60 15.76 0.006
Asymptomatic hyperuricemia 27.17 3.69 −2.72 10.10 0.260
First Metatarsal Normouricemic control 56.24
Gout 54.24 −2.00 −9.50 5.50 0.601
Asymptomatic hyperuricemia 60.25 4.01 −3.28 11.29 0.281
Second Metatarsal Normouricemic control 77.61
Gout 70.66 −6.95 −14.49 0.59 0.071
Asymptomatic hyperuricemia 82.15 4.54 −2.80 11.89 0.225
Third to Fifth Metatarsals Normouricemic control 66.61
Gout 61.00 −5.61 −12.90 1.68 0.132
Asymptomatic hyperuricemia 64.42 −2.18 −9.28 4.92 0.547
Hallux Normouricemic control 40.66
Gout 34.75 −5.91 −13.11 1.29 0.108
Asymptomatic hyperuricemia 41.74 1.08 −5.94 8.09 0.764
Lesser Toes Normouricemic control 21.92
Gout 23.19 1.28 −4.94 7.49 0.687
Asymptomatic hyperuricemia 20.48 −1.44 −7.50 4.62 0.642
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to previous research assessing people with gout during
shod walking [13], the current study also observed re-
duced heel pressures in participants with gout. This is
consistent with the slower walking speed and may reflect
an attempt to reduce impact at weight acceptance in the
absence of protective footwear.
When compared to normouricemic healthy control
participants, people with asymptomatic hyperuricemia
also exhibited altered gait parameters. They demon-
strated an increased base of support, spent more time in
double support, less time in single support and swing
phases and walked with increased cadence. An increased
base of support and double support duration are gener-
ally interpreted as adaptions made to produce a more
stable and safer gait in older adults who experience
mobility limitations [33–35]. The increased cadence also
observed in people with asymptomatic hyperuricemia
may reflect an attempt to maintain gait velocity while
retaining balance and stability. The findings from this
study may provide laboratory-based biomechanical sup-
port of patient-reported outcomes in which people with
asymptomatic hyperuricemia have reported reduced
lower limb function and increased activity limitation
compared to normouricemic control participants [14].
Participants with asymptomatic hyperuricemia also dif-
fered significantly from normouricemic control partici-
pants in terms of plantar pressure distribution in which
increased pressures in the midfoot and medial metatarsals
were observed. Increased midfoot pressures are character-
istic of flatter foot postures [36, 37] which have been
observed in people with asymptomatic hyperuricemia
[14]. This increase in fore- and mid-foot plantar pres-
sure is consistent with that observed in obese individ-
uals [38–40]. However, it should be noted that the analyses
in the current study were controlled for BMI. Furthermore,
obesity tends to also present with higher toe and heel pres-
sures [38, 40], which were not observed in the current
study, suggesting that other factors are driving functional
changes in people with asymptomatic hyperuricemia.
The findings from this study should be considered in
light of several limitations. Firstly, the participants with
gout were recruited from secondary care clinics and may
not be representative of those with less severe gout seen
in primary care. We did not match groups for BMI, and
BMI was higher in the participants with gout and
asymptomatic hyperuricemia, compared with the nor-
mouricemic control group. Importantly, BMI was in-
cluded in the analysis models. We cannot exclude the
possibility that BMI associated with hyperuricemia had
additional unmeasured impact on foot function. Also,
we did not exclude participants with diabetes or a loss of
peripheral sensation, which may have influenced plantar
pressure values in people with gout, reflecting the fre-
quent comorbid conditions observed in clinical practice.
This study highlights the need for future research to
provide insight into the dynamic function of the foot,
which may assist in the development of interventions for
pressure-related foot complaints in people with gout.
The relationship between lower limb function during
gait and specific locations of joint involvement in gout
may also contribute to knowledge in this field of re-
search. An understanding of the impact of comorbid
conditions in people with asymptomatic hyperuricemia
on functional limitation may also be of interest. The
efficacy of non-pharmacological interventions, in com-
bination with pharmacological treatment, aimed at im-
proving lower limb function and patient-reported pain
and disability in individuals with gout and asymptomatic
hyperuricemia also warrants further investigation.
Conclusions
In summary, the findings from this study provide novel
information regarding plantar pressure distribution dur-
ing barefoot walking in individuals with gout. The find-
ings are consistent with previous biomechanical research
in gout in which patients walk slower with increased
midfoot and decreased hallux peak pressures which are
suggestive of apropulsive and antalgic gait strategies.
This is the first study to assess gait and plantar pressure
characteristics in individuals with asymptomatic hyper-
uricemia. The results have shown that even in the ab-
sence of symptomatic gout, people with hyperuricemia
exhibit altered gait strategies and plantar loading which
may reflect their previously reported high levels of lower
limb impairment and disability.
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